IMV Inc

What IMV Inc does

IMV Inc. is a clinical-stage biopharmaceutical company headquartered in Halifax, Canada, founded in 2000 and publicly listed on the TSX Venture Exchange under the ticker CVE:IMV. The company applies a proprietary vaccine delivery platform to develop immunotherapeutic candidates spanning three distinct therapeutic areas: cancer therapy, infectious diseases, and animal health. Its primary commercial focus is on oncology, addressing healthcare providers and institutions pursuing novel immunotherapies that leverage the immune system to recognize and destroy cancer cells. The platform's multi-vertical applicability is structurally embedded in the value proposition, providing multiple potential paths to value but adding execution complexity across distinct regulatory and commercial pathways.

The company's core technology is a proprietary vaccine delivery platform from which product candidates are designed and progressed through clinical development. As a clinical-stage enterprise with no approved products, IMV does not currently generate commercial product revenue. Its business model is fundamentally capital-markets driven: pipeline advancement is funded through a combination of equity private placements and structured debt. Documented equity participation includes Altium Capital, Fonds de solidarité FTQ, Lumira Ventures, and CTI Life Sciences Fund, with cumulative disclosed equity capital of approximately US$46 million raised across rounds dating from 2013 to 2020.

In December 2021, IMV secured a US$25 million long-term debt facility led by Horizon Technology Finance Corporation, consisting of an initial US$15 million draw and a US$10 million tranche contingent on a milestone, accompanied by warrant issuance. The company operates with 51-100 employees and positions its oncology pipeline for the global personalized cancer vaccine market, which is projected to grow from approximately US$208 million in 2024 to US$8.5 billion by 2034 at a 44.9% CAGR.

Name

IMV Inc

Website

https://imvaccine.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

IMV Inc. is a clinical-stage biopharmaceutical company that applies a proprietary vaccine delivery platform to develop immunotherapies for cancer, infectious diseases, and animal health, primarily serving oncology-focused healthcare providers and institutions.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals (Cancer Immunotherapy)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Cancer immunotherapy
• Clinical-stage biopharmaceuticals
• Novel vaccine platform
• Infectious disease vaccines
• Animal health vaccines

Headquarters

HQ city

Halifax

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

IMV Inc. applies its novel proprietary delivery platform to develop immunotherapeutic vaccines for cancer therapy, infectious diseases, and animal health. The company is clinical-stage and focuses on leveraging its platform technology to elicit targeted immune responses against cancer cells and pathogens.

Product overview

IMV Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The sources indicate the company is advancing clinical development programs in cancer immunotherapies but do not provide specific named products, product modules, or detailed portfolio information.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Immunotherapy Vaccines Clinical-stage immunotherapeutic vaccine candidates that leverage IMV's proprietary delivery platform to elicit targeted immune responses against cancer cells. Developed for healthcare providers and patients in oncology.
• Infectious Disease Vaccines Vaccine candidates developed using IMV's novel delivery platform for infectious disease applications.
• Animal Health Vaccines Vaccine candidates developed using IMV's proprietary platform for veterinary and animal health applications.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves2 records

Expansion highlights4 records

Emerging players

• Arcturus Therapeutics: Clinical-stage mRNA and nucleic acid platform company with vaccine programs in infectious disease and oncology. Comparable as a smaller-cap platform vaccine developer with similar stage profile to IMV.
• Genexine: Clinical-stage company developing novel immunotherapies and therapeutic vaccines using proprietary platforms. Comparable to IMV as a smaller platform-based vaccine developer pursuing oncology and infectious disease applications.
• Transgene: Clinical-stage company developing viral vector-based therapeutic cancer vaccines and immunotherapies. Comparable to IMV in therapeutic vaccine modality and oncology focus at similar stage.

Broad incumbents

• Bristol Myers Squibb: Large pharmaceutical company with deep immuno-oncology portfolio (Opdivo, Yervoy) and active cancer vaccine interest. Comparable as a broad incumbent defining the competitive landscape for IMV's oncology vaccine work.
• Merck & Co. Large pharmaceutical company with leading immuno-oncology franchise (Keytruda) and a strategic partnership with Moderna on personalized cancer vaccines. Comparable as the dominant incumbent shaping the personalized cancer vaccine market IMV targets.

Direct peers

• CureVac: Clinical-stage mRNA platform company developing cancer vaccines and infectious disease vaccines. Comparable to IMV's platform-based vaccine approach across oncology and infectious disease.
• BioNTech: Clinical-stage and commercial mRNA-based immunotherapy company developing personalized cancer vaccines and infectious disease vaccines. Directly comparable to IMV's proprietary vaccine platform targeting oncology and infectious disease.
• Moderna: Platform mRNA company with cancer vaccine programs (e.g., mRNA-4157 with Merck) and infectious disease vaccines. Comparable to IMV as a platform-based vaccine developer pursuing multiple therapeutic areas.
• Gritstone bio: Clinical-stage developer of personalized neoantigen cancer vaccines using a proprietary delivery platform. Closely comparable to IMV in target indication, personalization approach, and clinical-stage status.

Regional players

• Elanco Animal Health: Large animal health company with a vaccine portfolio across livestock and companion animals. Comparable to IMV's animal health vaccine initiative as the dominant commercial counterpart that would be a natural partner or acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks5 records

Key highlights2 records

Customer concentration

• Xx.com/Immunovaccine
• Facebookfacebook.com/224346854247738
• LinkedInlinkedin.com/company/imv-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMV Inc